“…In recent years, advances in nanomaterials‐based drug delivery carriers have paved the way for overcoming these obstacles (Deldar, Zarghami, Pilehvar‐Soltanahmadi, Dadashpour, & Zarghami, ; Farajzadeh et al., ; Montazeri et al., ). The main advantages of nanocarriers for anticancer drugs include improved therapeutic effect, extended half‐life in the bloodstream, increased water solubility, improved stability, selective delivery to specific site, and decreased hepatotoxicity (Firouzi‐Amandi et al., ; Jalilzadeh‐Tabrizi et al., ; Nejati‐Koshki, Mortazavi, Pilehvar‐Soltanahmadi, Sheoran, & Zarghami, ; Zamani, Pilehvar‐Soltanahmadi, Alizadeh, & Zarghami, ).…”